14 October 2024.

Atmo Biosciences is pleased to announce that it has been awarded funding through the ANDHealth+ Stage 2 Commercialization Program, aimed at helping five digital health companies scale their products nationally and internationally.

The highly selective program will provide the cohort of companies collectively with up to A$3.75 million in non-dilutive funding to support commercialization.

ANDHealth+ is the flagship program of ANDHealth, Australia’s National Digital Health Accelerator Program. Funded by the Medical Research Future Fund (MRFF), ANDHealth+ is the leading dedicated digital health commercialization support program in Australia.
Atmo Biosciences CEO and President Mal Hebblewhite said Atmo is appreciative of the ongoing support provided by ANDHealth and this program in the form of funding, and access to a world-class network of experts.

“The ANDHealth+ program is helping Atmo develop healthcare economics and other supporting evidence to effectively prepare for US market entry and to aid with reimbursement of our product. We look forward to continuing this important work with ANDHealth and their team of experts to support commercialisation.” Mr. Hebblewhite said.

ANDHealth CEO and Managing Director, Bronwyn Le Grice said: “ANDHealth+ is a highly competitive program and the selection panel has been impressed by the increasingly high quality of applications over time.”

“These five exceptional companies will receive targeted expert advice and mentoring from international industry leaders, specialized commercialisation expertise, and significant non-dilutive funding to generate the clinical and commercial evidence required to scale their digital health products and services nationally and internationally,” Ms. Le Grice said.

The Atmo Gas Capsule System is currently an investigational device exclusively for use in clinical investigations. The Atmo Gas Capsule System is pending FDA 510(k) clearance and is not available for sale.